+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Intensity-modulated radiation therapy (IMRT) with concurrent taxane-based chemotherapy for locally-advanced head and neck cancer(LAHNC): Feasibility, technique, and toxicities



Intensity-modulated radiation therapy (IMRT) with concurrent taxane-based chemotherapy for locally-advanced head and neck cancer(LAHNC): Feasibility, technique, and toxicities



Journal of Clinical Oncology 23(16_Suppl): 5536-5536



NlmCategory="UNASSIGNED">5536 Background: Chemotherapy given concurrently with radiation is proven to improve tumor survival in LAHNC at the expense of higher toxicity. IMRT for LAHNC provides a means to minimize dose to sensitive organs. Our initial experience with concurrent IMRT and taxane-based chemotherapy in 83 LAHNC patients is presented. In order to simplify IMRT planning, a differential IMRT dose plan is developed for all head and neck structures. Daily fractions of 2.1Gy are delivered to gross disease with +/-5% homogeneity (69.3Gy in 33 fxs), simultaneously with 1.7Gy to prophylactic nodes (56.1Gy, homo +8 to -5%). 50% of the volume of sensitive tissue (oral cavity, parotids, back of neck, and larynx/trachea) are limited to ≤25Gy. Weekly paclitaxel 30mg/m2 and carboplatin AUC 1 were given concurrently to all 83 patients, and 40 with N2 or N3 disease also received weekly induction chemotherapy with paclitaxel 60mg/m2 and carboplatin AUC2. Chemo was held for ANC<1000, plts<100k, or gr4 mucositis Results: All 83 patients had AJCC III or IV nonmetastic disease: sinus-5, NPC-9, OP-44, OC-6, larynx-13, hypo-6. This regimen is highly feasible. 2 patients discontinued treatment early into treatment for non-toxicity related reasons (progression in lungs). Only 2 patients required a radiation break greater than 1 week. 28% required temporary PEG (none long-term). Only one patient (T4N0 hypopharynx) is still trach-dependent but has good swallowing function. Grade 3 mucositis occurred in 57% (2%Gr4) and gr3 dermatitis in 37%. There were no pts with nadir sepsis nor sig nephropathy or GI toxicity. One patient with a large base of skull tumor died 1 month after completion from carotid rupture. Xerostomia is ≤gr1 in all patients. IMRT with paclitaxel and carbo for LAHNC is extremely feasible using differential IMRT target dosing. Doses to sensitive non-target structures (oral cavity, trachea/larynx, back of neck, parotids) can be minimized (≤25Gy) and dose homogeneity to gross tumor held within +/-5% to avoid long-term morbidity. Early toxicities are low. Tumor control and survival data will also be presented. No significant financial relationships to disclose.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 058133025

Download citation: RISBibTeXText

PMID: 27945260


Related references

Intensity-modulated radiation therapy (IMRT) with cocurrent taxane-based chemotherapy for locally-advanced head and neck cancer (LAHNC): Toxicities and efficacy. 2007

Hypothyroidism as a consequence of intensity-modulated radiation therapy (IMRT) with concurrent taxane-based chemotherapy for locally-advanced head and neck cancer (LAHNC). Journal of Clinical Oncology 26(15_Suppl): 6048-6048, 2016

Phase I study of induction chemotherapy followed by intensity-modulated radiation therapy (IMRT), accelerated fractionation (AF), simultaneous integrated boost (SIB), and concomitant high dose cisplatin for locally-advanced head and neck cancer (LAHNC). Journal of Clinical Oncology 26(15_Suppl): 6073-6073, 2016

Hypothyroidism as a consequence of intensity-modulated radiotherapy with concurrent taxane-based chemotherapy for locally advanced head-and-neck cancer. International Journal of Radiation Oncology Biology Physics 77(2): 468-476, 2010

Intensity-modulated radiation therapy with concurrent carboplatin and paclitaxel for locally advanced head and neck cancer: toxicities and efficacy. Oncologist 17(5): 673-681, 2012

Efficacy of concurrent cetuximab vs. 5-fluorouracil/carboplatin or high-dose cisplatin with intensity-modulated radiation therapy (IMRT) for locally-advanced head and neck cancer (LAHNSCC). Oral Oncology 50(10): 947-955, 2014

A Matched Pair Comparison of Intensity Modulated Radiation Therapy With Cetuximab Versus Intensity Modulated Radiation Therapy With Platinum-based Chemotherapy for Locally Advanced Head-and-Neck Cancer. International Journal of Radiation Oncology*biology*physics 84(3): S207-S208, 2012

A matched-pair comparison of intensity-modulated radiation therapy with cetuximab versus intensity-modulated radiation therapy with platinum-based chemotherapy for locally advanced head neck cancer. International Journal of Clinical Oncology 19(2): 240-246, 2014

Predictors of Recurrence After Intensity Modulated Radiation Therapy With Concurrent Chemotherapy for Locally Advanced Head-and-Neck Carcinomas. International Journal of Radiation Oncology*biology*physics 84(3): S469-S470, 2012

Treatment of locally advanced carcinomas of head and neck with intensity-modulated radiation therapy (IMRT) in combination with cetuximab and chemotherapy: the REACH protocol. Bmc Cancer 10: 651, 2010

Dose to the inferior pharyngeal constrictor predicts prolonged gastrostomy tube dependence with concurrent intensity-modulated radiation therapy and chemotherapy for locally-advanced head and neck cancer. RadioTherapy and Oncology 110(3): 435-440, 2014

A comparative analysis between sequential boost and integrated boost intensity-modulated radiation therapy with concurrent chemotherapy for locally-advanced head and neck cancer. Radiation Oncology 12(1): 13, 2017

Feasibility study of moderately accelerated intensity-modulated radiotherapy plus concurrent weekly cisplatin after induction chemotherapy in locally advanced head-and neck cancer. International Journal of Radiation Oncology Biology Physics 79(4): 1073-1080, 2011

Phase 2 trial of concurrent 5-fluorouracil, hydroxyurea, cetuximab, and hyperfractionated intensity-modulated radiation therapy for locally advanced head and neck cancer. Cancer 117(2): 318-326, 2011

Pre-trial quality assurance processes for an intensity-modulated radiation therapy (IMRT) trial: PARSPORT, a UK multicentre Phase III trial comparing conventional radiotherapy and parotid-sparing IMRT for locally advanced head and neck cancer. British Journal of Radiology 82(979): 585-594, 2009